ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
95.39 USD   +3.01%
07/01Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare, Industrial Tech, and Software Sectors
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/08Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Berenberg Bank Adjusts Ascendis Pharma's Price Target to $168 From $192, Maintains Buy Rating

05/16/2022 | 07:16am EDT


ę MT Newswires 2022
All news about ASCENDIS PHARMA A/S
07/01Berenberg Bank Suspends Coverage of 25 Companies in Consumer Discretionary, Healthcare,..
MT
06/28European ADRs Nudge Lower in Tuesday Trading
MT
06/08Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
AQ
06/07European ADRs Move Higher in Tuesday Trading
MT
06/07Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
AQ
06/03European ADRs Move Lower in Friday Trading
MT
06/01European ADRs Move Lower in Wednesday Trading
MT
05/27European ADRs Move Higher in Friday Trading
MT
05/24European ADRs Move Lower in Tuesday Trading
MT
05/24Ascendis Pharma - Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon h..
AQ
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 36,3 M 37,2 M 37,2 M
Net income 2022 -494 M -506 M -506 M
Net cash 2022 471 M 482 M 482 M
P/E ratio 2022 -10,5x
Yield 2022 -
Capitalization 5 045 M 5 168 M 5 168 M
EV / Sales 2022 126x
EV / Sales 2023 34,7x
Nbr of Employees 639
Free-Float 11,6%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 93,11 €
Average target price 141,60 €
Spread / Average Target 52,1%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-31.17%5 168
GILEAD SCIENCES, INC.-14.12%78 219
VERTEX PHARMACEUTICALS30.84%73 484
REGENERON PHARMACEUTICALS, INC.-5.72%64 152
WUXI APPTEC CO., LTD.-4.30%47 357
BIONTECH SE-38.91%38 276